Anuh Pharma Share Price Today | Stock Price & Anuh Pharma Share Screener
As of October 5, 2026, the live Anuh Pharma share price (NSE: ANUHPHR) is ₹84.15 on NSE and ₹84.10 on BSE, down 1.98% from the previous close, with shares trading between ₹83.70 and ₹88.49 in today's trading session, and a 52-week range of ₹67.00–₹96.74. Check Anuh Pharma 52-week for the annual price range and momentum. Use the Anuh Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Anuh Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹784 and net income of ₹44, with EBITDA of ₹72, an operating margin of 9.0% and a profit margin of 5.6%.
Anuh Pharma Share Price Chart
Track the current stock price of Anuh Pharma with an interactive chart. Analyse ANUHPHR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Anuh Pharma stock quote in one place.
The quote of ₹84.15 sits between the 52-week low of ₹67.00 and the 52-week high of ₹96.74, and the latest session moved -1.98% from the previous close.
Anuh Pharma Company Profile - Fundamental Screener
Screen Anuh Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ANUHPHR shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE489G01022.
Company Details
Classification
Identifiers and Leadership
Anuh Pharma Balance Sheet Screener
Screen ANUHPHR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹557, up from ₹507 in 2025.
Latest statistics put total assets at ₹557 and shareholder funds at ₹352, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 557 | 507 | 446 | 405 | 347 | 333 | 326 | 240 | 209 | 189 |
| Current Assets | 451 | 376 | 339 | 308 | 259 | 238 | 223 | 152 | 154 | 138 |
| Fixed Assets | 57 | 58 | 49 | 53 | 61 | 71 | 84 | 21 | 17 | 17 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 352 | 326 | 291 | 241 | 214 | 191 | 162 | 165 | 150 | 141 |
| Share Capital | 50 | 25 | 25 | 25 | 25 | 25 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 302 | 301 | 266 | 216 | 189 | 166 | 150 | 152 | 137 | 128 |
Anuh Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Anuh Pharma income statement and profit fundamentals. Analyze ANUHPHR quarterly results. Anuh Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹784 and net profit was ₹44, equal to earnings per unit of ₹4.40, at an operating margin of 9%.
In that period expenses were ₹712, interest cost ₹0 and tax ₹17. The next period listed, 2026-March, shows revenue of ₹776 and net profit of ₹41.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 784 | 776 | 671 | 659 | 534 | 492 | 443 | 311 | 325 | 246 | 214 | 330 | 289 |
| Expenses | 712 | 710 | 601 | 572 | 476 | 440 | 387 | 284 | 291 | 220 | 184 | 290 | 254 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 72 | 66 | 70 | 87 | 57 | 52 | 55 | 27 | 34 | 25 | 30 | 40 | 35 |
| Operating Profit % | 9.00% | 8.00% | 9.00% | 12.00% | 10.00% | 10.00% | 10.00% | 7.00% | 9.00% | 8.00% | 11.00% | 11.00% | 11.00% |
| Depreciation | 11 | 11 | 9 | 9 | 10 | 12 | 15 | 7 | 2 | 2 | 2 | 2 | 3 |
| Interest | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 60 | 54 | 61 | 78 | 48 | 39 | 39 | 19 | 32 | 23 | 28 | 38 | 32 |
| Tax | 17 | 13 | 14 | 18 | 11 | 9 | 10 | 5 | 9 | 7 | 8 | 12 | 10 |
| Net Profit | 44 | 41 | 47 | 60 | 36 | 31 | 28 | 14 | 23 | 17 | 20 | 26 | 22 |
| EPS | 4.40 | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 2.85 | 9.33 | 6.59 | 8.00 | 10.30 | 8.78 |
Anuh Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ANUHPHR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹3, and net cash flow was an outflow of ₹12.
Over the same period, investing activities provided ₹18 and financing activities used ₹26.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -3 | 37 | 13 | 54 | 29 | -19 | 49 | 7 | 2 | 26 |
| Investing Activities | 18 | -20 | 1 | -44 | -8 | 52 | -77 | 3 | 2 | -20 |
Financing and Net Cash | ||||||||||
| Financing Activities | -26 | -5 | -9 | -12 | -20 | -33 | 22 | -7 | -5 | -4 |
| Net Cash Flow | -12 | 12 | 5 | -2 | 2 | 0 | -5 | 4 | -1 | 2 |
Anuh Pharma Shareholding Pattern Screener
See Anuh Pharma shareholding pattern with promoter, FII, and DII holdings. Check Anuh Pharma promoter holding and ownership changes for ANUHPHR on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 71.80%, foreign institutions 0.01%, domestic institutions 0.00% and the public 23.49%, spread across 27,484 shareholders.
The shareholder count was 27,484 in 2026-Jun, compared with 27,425 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jul | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 71.80% | 71.80% | 71.82% | 71.82% | 69.92% | 69.92% | 69.92% | 69.92% |
Institutional Investors | ||||||||
| FII Holding | 0.01% | 0.05% | 0.00% | 0.00% | 0.03% | 0.04% | 0.04% | 0.02% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.49% | 23.57% | 23.74% | 23.86% | 25.83% | 25.89% | 25.92% | 26.02% |
| Other Holding | 4.71% | 4.59% | 4.44% | 4.33% | 4.23% | 4.16% | 4.13% | 4.04% |
| Shareholder Count | 27,484 | 27,425 | 27,889 | 28,250 | 26,157 | 24,257 | 24,235 | 24,048 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Anuh Pharma. Anuh Pharma dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹1.50 per unit for 2026-March, a yield of 1.75%, compared with ₹1.50 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹1.50, ₹1.50 and ₹2.50 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹1.50 | 1.75% |
| 2025-March | ₹1.50 | 2.24% |
| 2024-March | ₹2.50 | 3.35% |
| 2023-March | ₹2.00 | 1.63% |
| 2022-March | ₹1.75 | 4.40% |
| 2021-March | ₹1.50 | 3.49% |
| 2020-March | ₹2.75 | 6.09% |
| 2019-March | ₹2.75 | 9.44% |
| 2018-March | ₹2.75 | 8.14% |
| 2017-March | ₹2.50 | 6.39% |
Anuh Pharma Stock Index Membership - Nifty & Sensex
See which indices include Anuh Pharma stock. Check ANUHPHR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Anuh Pharma Market Events Screener - Corporate Actions
Get Anuh Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Anuh Pharma stock events that may affect ANUHPHR share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated August 12, 2026, with a record date of August 12, 2026.
It is followed by Quarterly Result Announcement dated August 7, 2026 and Dividend dated August 5, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-12 | 2026-08-12 | Annual General Meeting | NA | -2.51% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | -0.45% |
| 2026-08-05 | 2026-08-05 | Dividend | ₹ 1.50 /share | 1.07% |
| 2026-05-20 | 2026-05-20 | Quarterly Result Announcement | NA | 0.78% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | 7.85% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -3.79% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | -13.23% |
| 2025-08-14 | 2025-08-15 | Dividend | ₹ 1.50 /share | -16.76% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -7.61% |
| 2025-07-15 | 2025-07-15 | Bonus | 1:1 | -5.91% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | 17.41% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 5.24% |
| 2024-11-08 | 2024-11-08 | Quarterly Result Announcement | NA | 5.11% |
| 2024-08-23 | 2024-08-23 | Annual General Meeting | NA | -12.70% |
| 2024-08-16 | 2024-08-16 | Dividend | ₹ 2.50 /share | -13.94% |
Anuh Pharma Competitors Screener - Peer Stocks Comparison
Screen ANUHPHR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Anuh Pharma Company Announcements - News & Reports Screener
Screen ANUHPHR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated September 18, 2026 and August 19, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Closure of Trading Window | - |
| 2026-09-18 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR) | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-14 | Announcement Under Regulation 30 - General Updates | - |
| 2026-08-14 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-12 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | Announcement Under Regulation 30 (LODR) - Adoption Of Revised Policy Of Related Party Transactions | - |
| 2026-08-07 | Announcement Under Regulation 30 (LODR) - Intimation Regarding The Request Received For Withdrawal Of Application For Reclassification. | - |
| 2026-08-07 | Results - Financial Results For June 30 2026 | - |
| 2026-08-07 | Board Meeting Outcome for Board Meeting Outcome For The Board Meeting Held On 07/08/2026 | - |
| 2026-08-03 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended 30Th June 2026. | - |
| 2026-07-18 | General Updates | - |
| 2026-07-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-18 | Reg. 34 (1) Annual Report. | - |
| 2026-07-18 | Shareholder Meeting - Annual General Meeting On Wednesday 12Th August 2026 | - |
| 2026-07-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-20 | Clarification For Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹84.15, within a 52-week range of ₹67.00 to ₹96.74. The P/E ratio is 19.89 and the P/B ratio is 2.50, with earnings per unit of ₹4.10. Market capitalisation stands at ₹860.42 Cr and the dividend yield is 1.71%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.